Skip to content
sellWeak cluster of 310b5-1 plan

Paul A Friedman sold $48M of MDGL

director at MADRIGAL PHARMACEUTICALS, INC.. 129,172 shares at an average of $370.24, traded Aug 13, 2025, filed Aug 13, 2025.

Warning score
30
Value
$48M
129,172 shares
Holdings after
187,164
-41% from before
From 52-week low
+84%
low $202.48, close $373.46
From 52-week high
0%
high $373.46, as of Aug 13, 2025

Score components

  • Role
    Director
    +15
  • Trade size
    $47.8M at market
    +25
  • Share of holdings sold
    Sold 41% of holdings
    +10
  • Cluster
    3 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

MDGLOct 9, 2026 · close 471.75
Since filing Aug 13, 2025: +26.3%SPY +22.4% · excess +3.9%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001236927-25-000007, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Aug 13, 2025MOption exercise
Common Stock10b5-1
+129,172$9.45$1.2M316,336Aug 13, 2025
Aug 13, 2025SOpen-market sale
Common Stock10b5-1
-1,600$358.23$573k314,736Aug 13, 2025
Aug 13, 2025SOpen-market sale
Common Stock10b5-1
-455$359.31$163k314,281Aug 13, 2025
Aug 13, 2025SOpen-market sale
Common Stock10b5-1
-3,153$360.27$1.1M311,128Aug 13, 2025
Aug 13, 2025SOpen-market sale
Common Stock10b5-1
-1,754$361.13$633k309,374Aug 13, 2025
Aug 13, 2025SOpen-market sale
Common Stock10b5-1
-1,439$362.29$521k307,935Aug 13, 2025
Aug 13, 2025SOpen-market sale
Common Stock10b5-1
-2,591$363.08$941k305,344Aug 13, 2025
Aug 13, 2025SOpen-market sale
Common Stock10b5-1
-3,529$364.02$1.3M301,815Aug 13, 2025
Aug 13, 2025SOpen-market sale
Common Stock10b5-1
-1,716$365.19$627k300,099Aug 13, 2025
Aug 13, 2025SOpen-market sale
Common Stock10b5-1
-3,152$366.22$1.2M296,947Aug 13, 2025
Aug 13, 2025SOpen-market sale
Common Stock10b5-1
-7,119$367.31$2.6M289,828Aug 13, 2025
Aug 13, 2025SOpen-market sale
Common Stock10b5-1
-6,788$368.34$2.5M283,040Aug 13, 2025
Aug 13, 2025SOpen-market sale
Common Stock10b5-1
-7,992$369.44$3.0M275,048Aug 13, 2025
Aug 13, 2025SOpen-market sale
Common Stock10b5-1
-7,877$370.44$2.9M267,171Aug 13, 2025
Aug 13, 2025SOpen-market sale
Common Stock10b5-1
-22,710$371.53$8.4M244,461Aug 13, 2025
Aug 13, 2025SOpen-market sale
Common Stock10b5-1
-28,976$372.39$11M215,485Aug 13, 2025
Aug 13, 2025SOpen-market sale
Common Stock10b5-1
-24,166$373.35$9.0M191,319Aug 13, 2025
Aug 13, 2025SOpen-market sale
Common Stock10b5-1
-4,155$374.38$1.6M187,164Aug 13, 2025
Aug 13, 2025MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-129,172$0.00$00Aug 13, 2025

Related signals

Other insiders at MADRIGAL PHARMACEUTICALS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
30Weak
MDGLsell10b5-1
MADRIGAL PHARMACEUTICALS, INC.
William John Sibold
President and CEO
$6.2M
11,583 shares
-6%
46Moderate
MDGLbuy
MADRIGAL PHARMACEUTICALS, INC.
Baker Bros. Advisors LP
director
$25M
68,618 shares
+36%
46Moderate
MDGLbuy
MADRIGAL PHARMACEUTICALS, INC.
Baker Bros. Advisors LP
director
$37M
97,065 shares
+50%
33Weak
MDGLsell 310b5-1
MADRIGAL PHARMACEUTICALS, INC.
Shannon T Kelley
General Counsel
$480k
1,304 shares
-12%
60Notable
MDGLsell 3
MADRIGAL PHARMACEUTICALS, INC.
Kenneth Bate
director
$3.7M
10,000 shares
-79%
25Weak
MDGLsell 310b5-1
MADRIGAL PHARMACEUTICALS, INC.
Paul A Friedman
director
$17M
46,808 shares
-25%
0Weak
MDGLsell10b5-1
MADRIGAL PHARMACEUTICALS, INC.
Paul A Friedman
director
$490k
1,400 shares
-1%
10Weak
MDGLsell10b5-1
MADRIGAL PHARMACEUTICALS, INC.
Paul A Friedman
director
$10M
28,876 shares
-14%
40Moderate
MDGLsell 6
MADRIGAL PHARMACEUTICALS, INC.
Fred B Craves
director
$5.1M
15,470 shares
-4%
26Weak
MDGLsell 610b5-1
MADRIGAL PHARMACEUTICALS, INC.
Mardi Dier
SVP and CFO
$83k
258 shares
-2%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Paul A Friedman sold $48M of MDGL | InsiderTell